IPA Announces Resignation of Director

Rhea-AI Summary

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announces the resignation of Board member Paul Andreola, effective immediately, for personal reasons unrelated to the company. Andreola has been with the Board since 2018 and will not seek re-election at the upcoming annual general meeting. Jennifer Bath, CEO, expressed gratitude for his contributions, while Andreola remains optimistic about the company's future and intends to support it as a shareholder. The company focuses on novel antibody discovery and developing tailored solutions for diverse disease targets.

Positive

• Continued support from Paul Andreola as an engaged shareholder.
• Leadership transition may bring fresh perspectives.

Negative

• Loss of a Board member may create a gap in experience and continuity.

VICTORIA, British Columbia--(BUSINESS WIRE)-- IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) announced today that Paul Andreola, a member of the Board of Directors of IPA, has resigned, effective immediately, from the Company's Board of Directors for personal reasons unrelated to the Company.

“On behalf of the Company and the Board of Directors, I would like to thank Paul for serving on our Board of Directors. His insightful and experienced contributions were highly valued, and we wish Paul all the best in his future endeavours,” commented Jennifer Bath, President and Chief Executive Officer and director of the Company.

Mr. Andreola commented, “It has been a privilege to serve on the board since 2018. I leave the company with great optimism in its leadership and strategy and will continue to support IPA from the sidelines as an engaged shareholder.”

As a result of Mr. Andreola’s resignation, Mr. Andreola will no longer stand for re-election at the Company’s upcoming annual general meeting of shareholders.

About ImmunoPrecise Antibodies Ltd

ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company endeavors to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes.

For further information, visit www.immunoprecise.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109006650/en/

IPA investor contact:

LifeSci Advisors

John Mullaly

E-mail : jmullaly@lifesciadvisors.com

Source: ImmunoPrecise Antibodies Ltd.

FAQ

Why did Paul Andreola resign from ImmunoPrecise Antibodies Ltd.?

Paul Andreola resigned for personal reasons unrelated to the company.

What impact does Paul Andreola's resignation have on ImmunoPrecise Antibodies Ltd.?

His resignation may create a gap in experience and continuity, though he remains supportive as a shareholder.

When will Paul Andreola's resignation take effect?

Paul Andreola's resignation is effective immediately.

Will Paul Andreola stand for re-election?

No, Paul Andreola will not stand for re-election at the upcoming annual general meeting of shareholders.

Who commented on Paul Andreola's resignation?

Jennifer Bath, the President and CEO of ImmunoPrecise Antibodies Ltd., commented on the resignation.